ArticleNature2022
The co-evolution of the genome and epigenome in colorectal cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
12.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Machine learning-based meta-analysis of colorectal cancer and inflammatory bowel disease.PloS one · 2023Pooled it
- DNA methylation signatures of sporadic colorectal cancer with microsatellite instability.Epigenetics · 2026Article
- RAS pathway mutations orchestrate chromatin reconfiguration and transcriptional rewiring in colorectal cancer.Cell communication and signaling : CCS · 2026Article
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Deep Learning-Assisted Prioritization of Candidate Drug Targets in Tumors Using Spatial Multi-Omics.Biology · 2026Review
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Nuclear factor of activated T cells as a driver of tumor progression and a target for precision therapy.Animal models and experimental medicine · 2026Review
- Clonal evolution and mutational trajectories of metastatic colorectal cancer shaped by anticancer therapies.Nature communications · 2026Article
- N7-Methylguanosine Modification in Colorectal Cancer: Molecular Insights and Clinical Implications.International journal of molecular sciences · 2026Review
- cfDECOR: a novel approach for estimating cell type contributions to cfDNA based on chromatin accessibility patterns.Scientific reports · 2026Article
- Review
- Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer.Molecular oncology · 2026Article
- Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation.Genome medicine · 2026Article
- Full spatio-temporal analyses of migration and colonization in evolution-dense 3D mapping of cancer metastases provides new insights.Molecular biology and evolution · 2026Article
- Advances in Colorectal Cancer Cell Biology and Clonal Evolution.International journal of molecular sciences · 2026Review
- Nidogen 1-enriched extracellular vesicles promote liver metastasis by inducing EMT and activating stellate cells.iScience · 2025Article
- Epigenetically driven and early immune evasion in colorectal cancer evolution.Nature genetics · 2025Article
- Timing and mechanisms of immune evasion in colorectal cancers.Nature genetics · 2025Article
- A novel β-carboline alkaloid derivative targeting MDM2-p53 pathway suppresses colorectal cancer progression.Cellular oncology (Dordrecht, Netherlands) · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 4 countries.
Timon Heide *Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1386-7469
Jacob Househam *Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-3199-336X
George D CresswellCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-3303-068X
Inmaculada SpiteriCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1097-8972
Claire LynnCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Maximilian MossnerCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9751-3803
Chris KimberleyEvolution and Cancer Lab, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Javier Fernandez-MateosCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Bingjie ChenCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Luis ZapataCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Chela JamesCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Iros BarozziDepartment of Surgery and Cancer, Imperial College London, London, UK.
Ketevan ChkhaidzeCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Daniel NicholCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Vinaya GunasriCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-9292-6470
Alison BernerEvolution and Cancer Lab, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-1132-0275
Melissa SchmidtEvolution and Cancer Lab, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-7682-0932
Eszter LakatosCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-7221-6850
Ann-Marie BakerCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8905-9137
Helena CostaDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.
Miriam MitchinsonDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.
Rocco PiazzaDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.ORCID http://orcid.org/0000-0003-4198-9620
Marnix JansenDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0003-0645-564X
Giulio CaravagnaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Daniele RamazzottiDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Darryl ShibataDepartment of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
John BridgewaterUCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0001-9186-1604
Manuel Rodriguez-JustoDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0001-5007-1761
Luca MagnaniDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-7534-0785
Trevor A GrahamCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK. trevor.graham@icr.ac.uk.ORCID http://orcid.org/0000-0001-9582-1597
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK. andrea.sottoriva@fht.org.ORCID http://orcid.org/0000-0001-6709-9533
Institute of Cancer Research · GBUniversity College London · GBQueen Mary University of London · GBUniversity of Milano-Bicocca · ITComprehensive Cancer Center Vienna · ATCRUK Lung Cancer Centre of Excellence · GBImperial College London · GBUniversity of Southern California · USUniversity of Trieste · IT
Funding
Statistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul Marjoram · 2016 to 2026
$25.5MThe Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6MCancer Research UK 19771Cancer Research UK 22909Cancer Research UK 23110Cancer Research UK A19771Cancer Research UK A22909Cancer Research UK A23110Medical Research Council MR/P000789/1NCI NIH HHS P01 CA196569NCI NIH HHS U54 CA217376Wellcome TrustWellcome Trust 105104/Z/14/ZWellcome Trust 202778/Z/16/Z
Abstract
Colorectal malignancies are a leading cause of cancer-related death
Indexed as
Colorectal NeoplasmsEpigenomeGenome, HumanMutationAdenomaCCCTC-Binding FactorCell Transformation, NeoplasticChromatinHumansInterferonsOncogenesTranscription FactorsCCCTC-Binding FactorChromatinCTCF protein, humanInterferonsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.